中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01177 中国生物制药

休市中 04-19 16:08:35

2.340

-0.090

-3.70%

最高2.430	最低2.290	成交量1.34亿
今开2.400	昨收2.430	日振幅5.76%
总市值439.95亿	流通市值439.95亿	总股本188.01亿
成交额3.11亿	换手率0.71%	流通股本188.01亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01177","market":"HK","secType":"STK","nameCN":"中国生物制药","latestPrice":2.34,"timestamp":1713514115029,"preClose":2.43,"halted":0,"volume":133647456,"delay":0,"floatShares":18801217230,"shares":18801217230,"eps":0.13595141,"marketStatus":"休市中","marketStatusCode":7,"change":-0.09,"latestTime":"04-19 16:08:35","open":2.4,"high":2.43,"low":2.29,"amount":311442183,"amplitude":0.057613,"askPrice":2.34,"askSize":178000,"bidPrice":2.33,"bidSize":2436000,"shortable":3,"etf":0,"ttmEps":0.13595140804512162,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1713749400000},"adr":0,"adjPreClose":2.43,"dividendRate":0.020953,"openAndCloseTimeList":[[1713490200000,1713499200000],[1713502800000,1713513600000]],"volumeRatio":1.7962234334618157,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"SBO.HK"},"requestUrl":"/m/hq/s/01177","defaultTab":"news","newsList":[{"id":"2428063187","title":"中国生物制药(01177)：受托人根据限制性股份奖励计划进一步购买500万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2428063187","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2428063187?lang=zh_cn&edition=full","pubTime":"2024-04-19 18:11","pubTimestamp":1713521480,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药(01177)发布公告，于2024年4月19日，受托人从市场进一步购买500万股股份，并根据计划规则的条款及条件代获选参与者以信托持有。每股股份平均代价约2.339港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1105500.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2428333706","title":"中国生物制药(01177)4月19日斥资1168.2万港元回购500万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2428333706","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2428333706?lang=zh_cn&edition=full","pubTime":"2024-04-19 17:04","pubTimestamp":1713517484,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药(01177)发布公告，于2024年4月19日该公司斥资1168.2万港元回购500万股，回购价格为每股2.32-2.34港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1105392.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2428577272","title":"中国生物制药盘中异动 早盘快速下挫5.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2428577272","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428577272?lang=zh_cn&edition=full","pubTime":"2024-04-19 10:41","pubTimestamp":1713494489,"startTime":"0","endTime":"0","summary":"2024年04月19日早盘10时41分，中国生物制药股票出现异动，股价急速下挫5.39%。截至发稿，该股报2.300港元/股，成交量3921.36万股，换手率0.21%，振幅5.35%。中国生物制药股票所在的药品行业中，整体跌幅为0.28%。其相关个股中，中生联合、培力农本方、精优药业涨幅较大，振幅较大的相关个股有三爱健康集团、君圣泰医药-B、中国同辐，振幅分别为10.00%、9.29%、6.81%。中国生物制药公司简介：中国生物制药有限公司是一间主要从事药品业务的投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240419104129861e7552&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240419104129861e7552&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428562237","title":"中国生物制药(01177)：1类创新药罗伐昔替尼片“ROVADICITINIB (TQ05105)”关键注册研究取得阳性结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2428562237","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2428562237?lang=zh_cn&edition=full","pubTime":"2024-04-18 19:35","pubTimestamp":1713440100,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告，该集团自主研发的1类创新药罗伐昔替尼片“Rovadicitinib ”用于治疗中高危骨髓纤维化 的关键注册临床研究已达到主要终点。集团将于近期递交TQ05105片的上市申请。该集团于2023年美国血液学年会公布了TQ05105用于治疗骨髓增殖性肿瘤的I期临床研究数据。集团在骨髓纤维化领域还布局了多项联合研究，如TQ05105联合BET抑制剂或BCL-2抑制剂，用于治疗中高危骨髓纤维化的临床研究，初步结果较为积极。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1104781.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2428814531","title":"中国生物制药(01177)出现大手卖出99万股，成交价$2.45，涉资242.55万","url":"https://stock-news.laohu8.com/highlight/detail?id=2428814531","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2428814531?lang=zh_cn&edition=full","pubTime":"2024-04-18 13:37","pubTimestamp":1713418620,"startTime":"0","endTime":"0","summary":"[大手成交]中国生物制药(01177)在下午01:37出现大手卖出，成交量为99万，成交价为港币$2.45，涉资242.55万。至目前为止，股价跌0.407%，今日最高价为$2.48，而最低价为$2.41，总成交量为4.583千万股，总成交金额港币$1.127亿。","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180205145554547_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180205145554547_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2404183626/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2428391779","title":"【港股通】中生制药(01177)：限制性股份奖励计划受托人购买500万股 每股平均代偿2.459港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2428391779","media":"金吾资讯","top":-1,"share":"https://www.laohu8.com/m/news/2428391779?lang=zh_cn&edition=full","pubTime":"2024-04-17 17:16","pubTimestamp":1713345392,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中国生物制药(01177)公告，限制性股份奖励计划受托人今日(17日)从市场进一步购买500万股股份，每股股份平均代偿2.459港元，购买股份总代价为1229.51万港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041717180387883bba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041717180387883bba&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428649043","title":"【港股通】中生制药(01177)跌超3% 汇丰研究微削其今明两年收入预测","url":"https://stock-news.laohu8.com/highlight/detail?id=2428649043","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2428649043?lang=zh_cn&edition=full","pubTime":"2024-04-17 15:06","pubTimestamp":1713337590,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中生制药(01177)股价震荡走低，截止发稿，跌3.54%，报2.45港元，成交额1.82亿港元。汇丰环球研究发研指，预计中生制药在新药上市和业务前景可观支持下得到持续增长，今明两年的收入和经调整净利润将分别增长低双位数。当中，由于集团持续分拆非核心业务，将其2024至25年收入预测削减10%。2024至2026年的收入预测分别为290亿、320亿及350亿元人民币。该行又将中生制药经调整净利润预测下调15%，即2024至2026年的经调整净利润分别为29亿、32亿及35亿元人民币。该行将中生制药目标价由4.6港元微降至4.5港元，维持“买入”评级。","market":"sh","thumbnail":"https://static.szfiu.com/news/20210810/NTc5ODJhYWQ2MDcxZDU1Zjc2OTIwMzU3MzY2MTU5Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NTc5ODJhYWQ2MDcxZDU1Zjc2OTIwMzU3MzY2MTU5Ng==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1935243","is_publish_highlight":false,"gpt_icon":0},{"id":"2428135961","title":"中国生物制药(01177)出现大手买入82.7万股，成交价$2.48，涉资205.096万","url":"https://stock-news.laohu8.com/highlight/detail?id=2428135961","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2428135961?lang=zh_cn&edition=full","pubTime":"2024-04-17 11:34","pubTimestamp":1713324840,"startTime":"0","endTime":"0","summary":"[大手成交]中国生物制药(01177)在上午11:34出现大手买入，成交量为82.7万，成交价为港币$2.48，涉资205.096万。至目前为止，股价跌2.362%，今日最高价为$2.57，而最低价为$2.46，总成交量为3.747千万股，总成交金额港币$9.45千万。","market":"other","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180205145552499_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180205145552499_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2404173323/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2427172648","title":"中国生物制药(01177)4月16日斥资1270万港元回购500万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2427172648","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2427172648?lang=zh_cn&edition=full","pubTime":"2024-04-16 16:36","pubTimestamp":1713256608,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药(01177)发布公告，于2024年4月16日该公司斥资1270万港元回购500万股股份，每股回购价格为2.54港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1103267.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2427947568","title":"中国生物制药盘中异动 股价大跌5.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2427947568","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427947568?lang=zh_cn&edition=full","pubTime":"2024-04-16 13:37","pubTimestamp":1713245872,"startTime":"0","endTime":"0","summary":"2024年04月16日下午盘13时37分，中国生物制药股票出现异动，股价大幅下挫5.22%。截至发稿，该股报2.541港元/股，成交量5079.41万股，换手率0.27%，振幅5.22%。中国生物制药股票所在的药品行业中，整体跌幅为0.24%。其相关个股中，联康生物科技集团、泰凌医药、中智药业涨幅较大，振幅较大的相关个股有君圣泰医药-B、三爱健康集团、中生联合，振幅分别为17.60%、13.79%、13.64%。中国生物制药公司简介：中国生物制药有限公司是一间主要从事药品业务的投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041613375287e80da5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041613375287e80da5&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427864905","title":"汇丰研究微降中生制药目标价至4.5元","url":"https://stock-news.laohu8.com/highlight/detail?id=2427864905","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2427864905?lang=zh_cn&edition=full","pubTime":"2024-04-16 10:35","pubTimestamp":1713234900,"startTime":"0","endTime":"0","summary":"汇丰环球研究发表研究报告指，中生制药与勃林格殷格翰在中国合作开发三个处于临床开发阶段的资产及若干早期临床资产。汇丰研究预计，中生制药在新药上市和业务前景可观支持下得到持续增长，今明两年的收入和经调整净利润将分别增长低双位数。该行又将中生制药经调整净利润预测下调15%，即2024至2026年的经调整净利润分别为29亿、32亿及35亿元人民币。该行将中生制药目标价由4.6元微降至4.5元，维持“买入”评级。","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220728114525438_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220728114525438_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1342546/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2427027907","title":"中生制药(01177.HK)受托人购买500万股  涉1,340.3万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2427027907","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2427027907?lang=zh_cn&edition=full","pubTime":"2024-04-15 17:42","pubTimestamp":1713174120,"startTime":"0","endTime":"0","summary":"中国生物制药(01177.HK) 公布，限制性股份奖励计划受托人今日(15日)从市场进一步购买500万股股份，每股平均价2.68元，涉额1,340.25万元。(da/u)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-15 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20190401142440189_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20190401142440189_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1342365/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2427502238","title":"【券商聚焦】银行证券首予中国生物制药(01177)“推荐”评级 指其创新产品步入业绩收获期","url":"https://stock-news.laohu8.com/highlight/detail?id=2427502238","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2427502238?lang=zh_cn&edition=full","pubTime":"2024-04-15 17:29","pubTimestamp":1713173383,"startTime":"0","endTime":"0","summary":"金吾财讯 | 银行证券发研指，2023年中国生物制药 营业总收入263.76亿元，归母净利润23.3亿元。仿制药业务是公司的基石板块，2018年“4+7”中核心产品恩替卡韦分散片中标降价90%以上，使院端四十亿以上销售额下降为个位数。此后，公司仍积极参与国家集采，目前3亿以上仿制药品种均已纳入集采范围，集采风险基本出清。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210810/MmVhZTZkMDM4NGVmNGFjNGI4NWVlMGI4Yzg3MDVjMjMzODE0Mjk0ODA4MTA0.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/MmVhZTZkMDM4NGVmNGFjNGI4NWVlMGI4Yzg3MDVjMjMzODE0Mjk0ODA4MTA0.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1935087","is_publish_highlight":false,"gpt_icon":0},{"id":"2427802979","title":"中国生物制药(01177)：受托人根据限制性股份奖励计划进一步购买500万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2427802979","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2427802979?lang=zh_cn&edition=full","pubTime":"2024-04-15 17:01","pubTimestamp":1713171660,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药(01177)发布公告，于2024年4月15日，受托人从市场进一步购买500万股股份，并根据计划规则的条款及条件代获选参与者以信托持有。每股股份平均代价约2.68港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1102541.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2427046325","title":"直击引领区丨“上海制造”生物药获欧盟与美国批准上市，勃林格殷格翰助力“中国创新”扬帆出海","url":"https://stock-news.laohu8.com/highlight/detail?id=2427046325","media":"浦东发布","top":-1,"share":"https://www.laohu8.com/m/news/2427046325?lang=zh_cn&edition=full","pubTime":"2024-04-15 14:03","pubTimestamp":1713161017,"startTime":"0","endTime":"0","summary":"近日，浦东跨国药企——勃林格殷格翰宣布位于上海浦东的勃林格殷格翰生物药业（中国）有限公司与客户合作，顺利通过了欧洲药品管理局和美国食品药品监督管理局的生产注册检查，获准向欧盟和美国两大市场供应勃林格殷格翰中国生物制药生产的创新生物药。勃林格殷格翰表示，十二年来与合作伙伴共同努力，顺利达成欧盟和美国生产许可获批里程碑。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240415140459877dff3d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240415140459877dff3d&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427034035","title":"中国银河证券：创新转型加速步入业绩收获期 首予中国生物制药(01177)“推荐”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2427034035","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2427034035?lang=zh_cn&edition=full","pubTime":"2024-04-14 20:40","pubTimestamp":1713098440,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国银河证券发布研究报告称，首次覆盖中国生物制药，给予“推荐”评级。中国银河证券主要观点如下：商业化能力突出的大型药企龙头，坚定创新战略转型。自研+BD+海外平台助力，创新转型加速步入业绩收获期。截至2023年年报，公司创新药管线内共有57款产品，未来三年内有望推出超过10款自研&BD创新药产品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1102259.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2427466527","title":"中国生物制药KRAS G12C靶向药D-1553展现显著疗效，预计成为国内首款","url":"https://stock-news.laohu8.com/highlight/detail?id=2427466527","media":"和讯网","top":-1,"share":"https://www.laohu8.com/m/news/2427466527?lang=zh_cn&edition=full","pubTime":"2024-04-13 18:54","pubTimestamp":1713005698,"startTime":"0","endTime":"0","summary":"港股领先药企中国生物制药近日宣布，其与益方生物合作研发的KRAS G12C靶向药物D-1553在美国癌症协会年会上展示了最新的2期临床试验结果。该药物针对携带KRAS G12C突变的非小细胞肺癌患者，在肿瘤缓解率和缓解持续时间方面表现出显著效果，同时在安全性方面也证明了良好的耐受性和可控性。这一进展意味着D-1553有望成为国内首个上市的KRAS G12C抑制剂，为广大患者带来新的治疗选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404131855008775557a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404131855008775557a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426206569","title":"中国生物制药(01177)：受托人根据限制性股份奖励计划进一步购买700万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2426206569","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2426206569?lang=zh_cn&edition=full","pubTime":"2024-04-12 17:25","pubTimestamp":1712913934,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药(01177)发布公告，于2024年4月12日，受托人从市场进一步购买700万股股份，并根据计划规则的条款及条件代获选参与者以信托持有，每股股份平均代价约2.73港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1101753.html","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sinobiopharm.com","stockEarnings":[{"period":"1week","weight":-0.1429},{"period":"1month","weight":-0.2571},{"period":"3month","weight":-0.2014},{"period":"6month","weight":-0.1236},{"period":"1year","weight":-0.4666},{"period":"ytd","weight":-0.3256}],"compareEarnings":[{"period":"1week","weight":-0.0298},{"period":"1month","weight":-0.0193},{"period":"3month","weight":0.0598},{"period":"6month","weight":-0.0552},{"period":"1year","weight":-0.2046},{"period":"ytd","weight":-0.0483}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"中国生物制药有限公司是一家主要从事药品业务的投资控股公司。该公司通过三个业务分部进行运营。中药现代制剂及西药分部从事生产、销售及配销中药现代制剂产品及西药产品业务。投资分部从事长期及短期投资业务。其他分部主要从事研发活动、向第三方提供服务以及从事相关医疗及医院业务。该公司还通过其子公司从事持有物业、销售健康食品、验光配镜以及零售与批发视光和听力产品业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.009982},{"month":2,"riseRate":0.666667,"avgChangeRate":0.059578},{"month":3,"riseRate":0.571429,"avgChangeRate":0.043859},{"month":4,"riseRate":0.47619,"avgChangeRate":0.019255},{"month":5,"riseRate":0.7,"avgChangeRate":0.038371},{"month":6,"riseRate":0.35,"avgChangeRate":0.003696},{"month":7,"riseRate":0.6,"avgChangeRate":0.029101},{"month":8,"riseRate":0.35,"avgChangeRate":-0.023106},{"month":9,"riseRate":0.35,"avgChangeRate":-0.024746},{"month":10,"riseRate":0.6,"avgChangeRate":0.036433},{"month":11,"riseRate":0.55,"avgChangeRate":0.076694},{"month":12,"riseRate":0.45,"avgChangeRate":-0.005852}],"exchange":"SEHK","name":"中国生物制药","nameEN":"SINO BIOPHARM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中国生物制药,01177,中国生物制药股票,中国生物制药股票老虎,中国生物制药股票老虎国际,中国生物制药行情,中国生物制药股票行情,中国生物制药股价,中国生物制药股市,中国生物制药股票价格,中国生物制药股票交易,中国生物制药股票购买,中国生物制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}